User profiles for Vasisht Srinivasan
 | Vasisht Srinivasan, MDActing Assistant Professor, University of Washington Verified email at uw.edu Cited by 1197 |
Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective …
Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …
[HTML][HTML] Clinical severity and mRNA vaccine effectiveness for omicron, delta, and alpha SARS-CoV-2 variants in the United States: a prospective observational study
Objectives To characterize the clinical severity of COVID-19 caused by Omicron, Delta, and
Alpha SARS-CoV-2 variants among hospitalized adults and to compare the effectiveness of …
Alpha SARS-CoV-2 variants among hospitalized adults and to compare the effectiveness of …
Associations between persistent symptoms after mild COVID‐19 and long‐term health status, quality of life, and psychological distress
…, CJ Lindsell, MN Gong, V Srinivasan… - Influenza and other …, 2022 - Wiley Online Library
Background We sought to assess whether persistent COVID‐19 symptoms beyond 6 months
(Long‐COVID) among patients with mild COVID‐19 is associated with poorer health status, …
(Long‐COVID) among patients with mild COVID‐19 is associated with poorer health status, …
mRNA vaccine effectiveness against coronavirus disease 2019 hospitalization among solid organ transplant recipients
Background The study objective was to evaluate 2- and 3-dose coronavirus disease 2019 (COVID-19)
mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among …
mRNA vaccine effectiveness (VE) in preventing COVID-19 hospitalization among …
[HTML][HTML] Vaccine effectiveness of primary series and booster doses against Omicron variant COVID-19-associated hospitalization in the United States
Objectives: To compare the effectiveness of a primary COVID-19 vaccine series plus a
booster dose with a primary series alone for the prevention of Omicron variant COVID-19 …
booster dose with a primary series alone for the prevention of Omicron variant COVID-19 …
Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures
…, EW Mueller, CD Philpott, V Srinivasan… - … : The Journal of …, 2022 - Wiley Online Library
Background Outcomes following andexanet alfa reversal of factor Xa inhibitors in patients
requiring urgent or emergent invasive procedures are lacking. This study aimed to describe …
requiring urgent or emergent invasive procedures are lacking. This study aimed to describe …
Factors associated with early withdrawal of life-sustaining treatments after out-of-hospital cardiac arrest: a subanalysis of a randomized trial of prehospital therapeutic …
Background The objective of this study is to describe incidence and factors associated with
early withdrawal of life-sustaining therapies based on presumed poor neurologic prognosis (…
early withdrawal of life-sustaining therapies based on presumed poor neurologic prognosis (…
Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the …
Background Test-negative design (TND) studies have produced validated estimates of vaccine
effectiveness (VE) for influenza vaccine studies. However, syndrome-negative controls …
effectiveness (VE) for influenza vaccine studies. However, syndrome-negative controls …
Absolute and relative vaccine effectiveness of primary and booster series of COVID-19 vaccines (mRNA and adenovirus vector) against COVID-19 hospitalizations in …
Background Coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) studies are
increasingly reporting relative VE (rVE) comparing a primary series plus booster doses with a …
increasingly reporting relative VE (rVE) comparing a primary series plus booster doses with a …
Effectiveness of the Ad26. COV2. S (Johnson & Johnson) coronavirus disease 2019 (COVID-19) vaccine for preventing COVID-19 hospitalizations and progression to …
Background . Adults in the United States (US) began receiving the adenovirus vector coronavirus
disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in …
disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), in …